Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975295 | 1.00 | PTGDR2 (0.52) | PTGDR2SCN9ATP53MAPT | |
| SCHEMBL22975274 | 0.93 | PTGDR2 (0.43) | PTGDR2SCN9A | |
| SCHEMBL22975275 | 0.93 | PTGDR2 (0.43) | PTGDR2SCN9A | |
| SCHEMBL22975305 | 0.91 | PTGDR2 (0.49) | PTGDR2TP53MAPT | |
| SCHEMBL22975308 | 0.91 | PTGDR2 (0.49) | PTGDR2TP53MAPT | |
| SCHEMBL22975249 | 0.90 | PTGDR2 (0.44) | PTGDR2TP53MAPT | |
| SCHEMBL22975252 | 0.90 | PTGDR2 (0.44) | PTGDR2TP53MAPT | |
| SCHEMBL22975267 | 0.90 | PTGDR2 (0.42) | PTGDR2TP53MAPT | |
| SCHEMBL22975270 | 0.90 | PTGDR2 (0.42) | PTGDR2TP53MAPT | |
| SCHEMBL22975302 | 0.87 | PTGDR2 (0.41) | PTGDR2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077540-B2 | Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230056205-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-23 | — | — | US | disclosed |
| US-11407752-B2 | Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione analogues | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | PTGDR2 393/4885SCN9A 3085/4885TP53 1672/4885 |
| US-20230056205-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | PTGDR2 386/4885SCN9A 3109/4885TP53 1646/4885 |
| US-11407752-B2 | Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione analogues | DHPS, HTR5A, QDPR | PTGDR2 405/4885SCN9A 3055/4885TP53 1751/4885 |
| US-12077540-B2 | Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues | DHPS, QDPR, HTR5A | PTGDR2 393/4885SCN9A 3085/4885TP53 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.